Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Thompson

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Scientific Reports|June 28, 2018
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicingSarah V Gerhart, Wendy A Kellner, Christine Thompson, et al.
Nature|October 12, 2012
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsMichael T McCabe, Heidi M Ott, Gopinath Ganji, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2Sharad K Verma, Xinrong Tian, Louis V LaFrance, et al.
Cancer Cell|August 14, 2019
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine MethylationJia Yi Fong, Luca Pignata, Pierre-Alexis Goy, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Scientific Reports|June 28, 2018
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicingSarah V Gerhart, Wendy A Kellner, Christine Thompson, et al.
Nature|October 12, 2012
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsMichael T McCabe, Heidi M Ott, Gopinath Ganji, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2Sharad K Verma, Xinrong Tian, Louis V LaFrance, et al.
Cancer Cell|August 14, 2019
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine MethylationJia Yi Fong, Luca Pignata, Pierre-Alexis Goy, et al.
Pageof 6